University of Pittsburgh Announces 9 U.S. Patents Issued to Pitt Innovators in September 2026
Pitt innovators were issued nine U.S. patents in September 2026. Featured patent: 12,746,528: Hydrogel... Read more
Pitt innovators were issued nine U.S. patents in September 2026. Featured patent: 12,746,528: Hydrogel... Read more
Pitt’s Senior Vice Chancellor for Research, Dr. Rob Rutenbar introduced MIT professor Robert Langer... Read more
REGENTYS™ is a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders. Their first product, ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
University of Pittsburgh
Powered by AI. Please verify important information.